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Utility of hepatic or total body 
iron burden in the assessment of 
advanced hepatic fibrosis in HFE 
hemochromatosis
Justin chin1*, Lawrie W. powell2, Louise e. Ramm3, oyekoya t. Ayonrinde1, Grant A. Ramm2,3,5 
& John K. olynyk1,4,5
Development of advanced hepatic fibrosis in HFE Hemochromatosis (HH) is influenced by hepatic iron 
concentration (HIC) and age. In patients with HH, it is important to assess the likelihood of cirrhosis 
and thus the need for confirmatory liver biopsy. Therapeutic phlebotomy also provides an estimate 
of mobilisable iron stores. We determined whether mobilisable iron stores may predict the presence 
of advanced fibrosis. Retrospective analysis of 137 male and 65 female HH subjects was undertaken. 
Biochemical, histological and phlebotomy data were available on all subjects. The mean values of HIC, 
HIC × [age], mobilisable iron, mobilisable iron × [age] and serum ferritin in the cohort were higher 
in the group with advanced fibrosis. HIC had an optimum sensitivity and specificity of 73% for the 
diagnosis of advanced liver fibrosis, with a cut-off HIC level of 200 µmol/g (AUROC 0.83, p < 0.0001). 
AUROC for HIC was greater in females (0.93) than males (0.79). Mobilisable iron had an optimum 
sensitivity and specificity both of 83% at a cut-off of 9.6 g for the prediction of advanced fibrosis in all 
subjects (AUROC 0.92, p < 0.0001). Mobilisable iron stores provide a simple, clinically useful indication 
of the risk of advanced fibrosis and should routinely be considered.
HFE Hemochromatosis (HH) is an autosomal recessive disorder of iron metabolism and is one of the most com-
mon genetic disorders in Caucasian populations, with a prevalence of 1 in 200 persons1,2. Accumulation of iron 
occurs in subjects with HH due to a homozygous C282Y substitution in the HFE gene product, which causes 
dysregulated hepatic hepcidin expression, resulting in unregulated iron absorption, leading to iron deposition in 
various tissues in the liver, heart and multiple other organs3. In a proportion of patients, untreated disease leads 
to end-organ damage, which includes the development of hepatic fibrosis or cirrhosis4. However, the phenotypic 
expression of iron overload is variable, with only a minority of patients with C282Y homozygosity developing 
symptoms and/or end organ damage related to severe iron overload5. In the liver, the diagnosis and identifica-
tion of individuals with underlying advanced fibrosis or cirrhosis is crucial for prognosis, since these subjects 
exhibit poorer long-term survival related to a variety of complications of chronic liver disease, as well as markedly 
increased risk of hepatocellular carcinoma6. Known risk factors associated with an increased risk of advanced 
fibrosis or cirrhosis in HH include excessive alcohol consumption, serum ferritin levels greater than 1000 µg/L, 
male gender, the presence of diabetes mellitus and hepatic iron concentration (HIC) greater than 236 µmol/g7–10.
Interestingly, an earlier study suggested that advanced fibrosis could develop in individuals with lower HIC 
levels than usually considered to pose a risk, and that this may be related to longer duration of exposure to ele-
vated hepatic iron11. This was confirmed by a subsequent study which demonstrated that the product of HIC and 
age improved the sensitivity and specificity for prediction of advanced fibrosis, when compared with HIC alone12.
While the measurement of HIC provides a quantitation of liver iron content, an approximation of total body 
mobilisable iron stores can be determined via therapeutic phlebotomy13. Each unit of blood (500 ml) removed 
during phlebotomy contains an estimated 200–250 mg of iron14. Thus, the total number of venesections required 
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to achieve a serum ferritin level in the order 50–100 µg/L allows for estimation of total body iron stores. The aim 
of the current study was to examine the relationships between HIC, mobilisable iron (with and without duration 
of iron loading) and the prediction of advanced fibrosis, to ultimately determine whether mobilisable iron stores 
could provide a useful clinical predictor of advanced fibrosis in an independent large cohort of well-characterized 
subjects with HH and thereby assist in determining whether more specific tests for advanced fibrosis are required, 
such as liver biopsy.
Patients and Methods
patients. We studied 202 consecutive subjects diagnosed with HH, and who underwent a liver biopsy at the 
Royal Brisbane and Women’s Hospital in Australia between 1972 and 2010 as part of routine standard of care for 
assessment of HH. Baseline demographic data, total number of venesections, alcohol consumption, biochemical 
results and liver biopsy histological assessments were available on all subjects. All subjects were confirmed as 
being C282Y homozygous on genetic testing. All subjects were routinely offered a liver biopsy as part of base-
line assessment, and only those who declined did not receive one. Phlebotomy was performed weekly on all 
subjects until a serum ferritin level of less than 100 µg/L was achieved. Following this, patients had venesection 
at a frequency determined by the treating physician. Mobilisable iron was calculated using the total number of 
venesections required (one unit = 500 ml) to achieve a serum ferritin less than 100 µg/L multiplied by 250 mg of 
iron. Exclusion criteria included, age less than 16 years, or other forms of chronic liver disease such as chronic 
viral hepatitis, immune-mediated liver and metabolic liver diseases. The age of subjects was defined as the age at 
which the liver biopsy was performed. All subjects were untreated at the time of their study inclusion and had an 
alcohol consumption of <210 g per week for males, and 140 g per week for females. HIC was measured by atomic 
absorption spectrophotometry on fresh liver biopsy specimens15. Paraffin-embedded sections were stained with 
haematoxylin and eosin and Perls’ Prussian blue method and reviewed by liver histopathologists with expertise 
in HH who classified fibrosis stage according to the grading system of Scheuer: F0–no fibrosis, F1–mild fibrosis 
with enlarged portal tracts, F2–moderate periportal and portal-portal septa but intact architecture, F3–severe 
fibrosis with architectural distortion; and F4–cirrhosis with architectural distortion16. For the purposes of this 
study, subjects with hepatic fibrosis stages F3 and F4 were combined and termed ‘advanced fibrosis’. These studies 
were approved by the Human Research Ethics Committees of the Royal Brisbane and Women’s Hospital and the 
QIMR Berghofer Medical Research Institute, Brisbane, Australia and informed written consent was obtained at 
the time of entry into the study.
Statistical analysis. All data are presented as the mean ± SEM unless otherwise specified. Student’s T-test or 
analysis of variance was used to analyse differences between groups and area under the receiver operator charac-
teristic (AUROC) curve analysis was performed for evaluation of sensitivity and specificity of HIC (µmol/g), HIC 
× [age] (µmol/g.yr), mobilisable iron (g), mobilisable iron × [age] (g.yr) and serum ferritin (µg/L) parameters for 
the detection of advanced fibrosis. Fisher’s exact test was used to compare proportions of patients according to the 
severity of liver fibrosis and the presence or absence of advanced fibrosis. All statistical tests were conducted using 
GraphPad Prism 7 (GraphPad Software, San Diego, CA). All p-values are reported as two-sided and statistical 
significance was assigned for p < 0.05. Best sensitivity and specificity of the various tests was determined at the 
point where the two values were most similar. This would provide for the best rule in and rule out values for each 
test. Comparisons between ROC curves were performed using the method described by Hanley and McNeil17. 
Multivariable logistic regression analysis, including variables that were statistically significantly different in uni-
variate analysis, was used to calculate the odds ratio (OR) for predictors of advanced fibrosis in subjects with HH.
Results
The baseline study characteristics of all subjects are presented in Table 1. The mean subject age was 42.8 ± 1.1 
years for males and 45.3 ± 1.8 years for females (p = 0.09). Sixty-eight percent of the study population were com-
prised of male subjects. The mean alcohol intake was significantly higher in males than females (p < 0.001), but 
within recommended safe consumption levels. Mean levels of HIC in the male group were significantly higher 
than that of the female group (209 ± 11.9 µmol/g versus 155.3 ± 14.3 µmol/g, p = 0.007), as were serum ferritin 
and transferrin saturation levels (Table 1). Advanced fibrosis (F3-F4) was more prevalent in male subjects. Age 
and alcohol intake were significantly higher in the subjects with advanced fibrosis (Table 2a). The mean values of 
HIC, HIC × [age], mobilisable iron, mobilisable iron × [age] and serum ferritin in the whole cohort (as well as 
male and female subgroups) were higher in the groups with advanced fibrosis (Table 2b).
The ROC curve analysis for the diagnosis of advanced fibrosis in HH males and females combined demon-
strated that HIC alone had equivalent optimum sensitivity and specificity values of 73%, with a cut-off HIC level 
of greater than 200 µmol/g (AUROC 0.83) (Table 3). In the analysis of male subjects alone, the AUROC was 0.79, 
with an optimum sensitivity and specificity of 74% and 68%, respectively, with a cut-off HIC level of greater than 
200µmol/g. In the analysis of female subjects, the AUROC was 0.93, with an equivalent optimum sensitivity and 
specificity both of 80% with a cut-off HIC of greater than 197 µmol/g.
The product of HIC and age allowed for the incorporation of the duration of exposure to iron into the predic-
tion of advanced fibrosis. The ROC curve analysis demonstrated that HIC × [age] had an optimum sensitivity 
and specificity of 73% and 74%, respectively, for the diagnosis of advanced liver fibrosis in HH in males and 
females combined (Table 3), with a cut-off HIC × [age] of greater than 9183 µmol/g.yr (AUROC 0.82). The 
optimum sensitivity and specificity in male subjects were both 70% (AUROC 0.79), with a cut-off HIC × [age] 
of greater than 9152 µmol/g.yr. The optimum sensitivity and specificity in female subjects was 100% and 87% 
(AUROC 0.97), respectively, with a cut-off HIC × [age] of greater than 10400 µmol/g.yr.
The ROC curve analysis for mobilisable iron in all subjects demonstrated an AUROC of 0.92, with sensitivity 
and specificity both of 83%, with a cut-off of more than 9.6 g for the prediction of advanced fibrosis (Table 3). In 
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male subjects, both the sensitivity and specificity were 79% with a cut-off of more than 10.8 g (AUROC 0.88). In 
female subjects, both the sensitivity and specificity were 79% with a cut-off of more than 9.9 g (AUROC 0.99).
The ROC curve analysis for the product of mobilisable iron × [age] in all subjects demonstrated a sensitiv-
ity and specificity of 87% and 88%, respectively, with a cut-off of 467 g.yr (AUROC 0.93) for the prediction of 
advanced fibrosis (Table 3). In male subjects both the sensitivity and specificity were 79% using a cut-off of more 
than 495 g.yr (AUROC 0.89). In female subjects, both the sensitivity and specificity were 100% using a cut-off of 
more than 577 g.yr (AUROC 1.00).
The ROC curve analysis for serum ferritin in all subjects demonstrated an equivalent sensitivity and specificity 
of 85%, with a cut-off of more than 1665 µg/L (AUROC 0.94) for the prediction of advanced fibrosis (Table 3). In 
male subjects the sensitivity and specificity were 82% and 81% respectively, using a cut-off of more than 1826 µg/L 
(AUROC 0.92). In female subjects, the sensitivity and specificity were 100% and 98% respectively, using a cut-off 
of more than 1665 µg/L (AUROC 0.99).
ROC curves for mobilisable iron, HIC, HIC × [age], mobilisable iron × [age] and serum ferritin were com-
pared using the method of Hanley and McNeil17. Mobilisable iron was significantly better than either HIC or HIC 
× [age] (Table 3). There were no significant differences between mobilisable iron and either mobilisable iron × 
[age] or serum ferritin levels.
The mean values of HIC, HIC × [age], mobilisable iron, mobilisable iron × [age] and serum ferritin are pre-
sented in box and whisker plots (Fig. 1), highlighting proposed cut-off levels for predicting advanced fibrosis. 
Figure 2 shows the similarly significant correlations between mobilisable iron and HIC (r = 0.67) and between 
mobilisable iron and serum ferritin (r = 0.66). A multivariable logistic regression analysis was undertaken for 
all subjects with HH examining age, HIC, alcohol intake, serum ferritin and mobilisable iron. Mobilisable iron 
Male Female p-value
N (%) 137 (67.8%) 65 (32.2%)
Mean age 42.8 ± 1.13 45.3 ± 1.8 0.09
Mean HIC (µmol/g)
Alcohol Intake (g/week)
Serum Ferritin (µg/L)
Transferrin Saturation (%)
209 ± 11.9
31.3 ± 3.3
1717 ± 109.4
83 ± 1.6
155.3 ± 14.3
16.9 ± 3.2
664 ± 74.9
76.9 ± 2.3
0.007
<0.001
<0.001
0.01
Fibrosis staging (%) 0.01
F0
F1
F2
F3
F4
65 (47.4)
19 (13.9)
16 (11.7)
10 (7.3)
27 (19.7)
47 (72.3)
8 (12.3)
5 (7.7)
1 (1.5)
4 (6.2)
Table 1. Baseline patient characteristics of HH subjects. Data presented as mean ± standard error of mean or 
proportions. HIC, hepatic iron concentration.
All subjects (F0-2) All subjects (F3-4) p-value 
Age 42.2 ± 1.1 47.2 ± 1.6 0.04
Alcohol intake (g/week) 21.1 ± 2.3 48.7 ± 7.5 <0.001
Transferrin saturation (%) 80.7 ± 1.6 82.8 ± 2.4 0.53
Sex
Males 74% 26% 0.002
Females 92% 8%
Mean HIC, HIC x [age], mobilisable iron, mobilisable iron x [age] and serum ferritin in HH subjects.
All subjects (F0-2) All subjects (F3-4) Males (F0-2) Males (F3-4) Females (F0-2) Females (F3-4)
Mean HIC (µmol/g) 139.5 ± 7.7 324 ± 22.7 150 ± 10.4 324 ± 23.7 113.5 ± 10.7 335 ± 83.4
p-value <0.0001 <0.0001 0.0001
HIC × [age] (µmol/g.yr) 5637 ± 384.2 13908 ± 1295 6019 ± 531.9 13598 ± 1333 5318 ± 501.4 22875 ± 3617
p-value <0.0001 0.0002 <0.0001
Mobilisable iron (g) 5 ± 0.3 15 ± 1.7 6.5 ± 0.4 15 ± 1.6 3.75 ± 0.3 18.75 ± 12.1
p-value <0.0001 <0.0001 <0.0001
Mobilisable iron × [age] 229.3 ± 14.3 778.2 ± 76.2 265.2 ± 20.6 777.6 ± 78 158 ± 13.4 778.2 ± 383.4
p-value <0.0001 0.0001 <0.0001
Serum ferritin (µg/L) 1181 ± 73.8 3142 ± 202.5 576.5 ± 56.1 2413 ± 431.3 951.2 ± 55.6 3088 ± 192.5
p-value <0.0001 <0.0001 <0.0001
Table 2. Mean age, alcohol intake, transferrin saturation and sex in HH subjects. Advanced fibrosis = F3-F4 
fibrosis, No advanced fibrosis = F0-F2 fibrosis. Data presented as mean ± standard error of mean or 
proportions. HIC, hepatic iron concentration.
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was shown to be a significant predictor of advanced fibrosis, after adjusting for age, sex, alcohol intake, HIC and 
serum ferritin (Table 4).
Discussion
HH is a common disease that has become more widely recognized since genotyping for the HFE mutation com-
menced in 1996. A majority of patients are now diagnosed earlier, well in advance of the development of overt 
symptoms or systemic complications, and many of them are being managed in the primary care setting by general 
practitioners. However, some patients are unfortunately diagnosed late with quite advanced disease, largely due 
to a low index of suspicion on the part of some primary care physicians and the fact that the key screening test for 
iron overload (serum ferritin levels) is not included in the standard medical biochemical analysis. Undiagnosed, 
and thus untreated, patients are at risk of significant life limiting complications of cirrhosis, as well as HCC. 
Thus the ongoing clinical challenge in patients with HH has been to stratify risk for iron overload and advanced 
fibrosis. Staging of hepatic fibrosis is traditionally established through assessment of liver histology requiring 
patients to accept the potential risks and complications of a biopsy. Additionally, the measurement of HIC via 
magnetic resonance imaging (MRI) has been shown to correlate well with liver biopsy-derived HIC, making 
the assessment of liver iron levels much less invasive, and potentially more accessible to patients12,18. The use of 
non-invasive measurements of fibrosis in other chronic liver diseases through MRI, elastography, or serum based 
biomarkers, has increased globally with increased availability, and reduced costs. These modalities have primarily 
been validated in patients with chronic viral hepatitis and non-alcoholic fatty liver disease. While some groups 
have attempted to assess the utility of a variety of different non-invasive biomarkers in patients with HH, most 
studies lack rigor due to inadequate sample size or the absence of biopsy validated fibrosis and the cut-off values 
for prediction of advanced fibrosis have not been clearly defined19. Unfortunately, potentially efficacious modali-
ties such as MRI elastography are not easily accessible outside of tertiary health care facilities and have associated 
high costs and limited availability. A study by Beaton et al. had demonstrated that prediction of cirrhosis could be 
performed reliably in the majority of patients utilizing the clinical parameters of serum ferritin above 1000 µg/L, 
with an elevated aminotransferase level and a platelet count of less than 200 × 109/L8. However, recent studies 
have suggested that approximately 30–64% of patients with cirrhosis do not fulfil all three criteria8,20. This could 
result in potential missed diagnosis and would still require patients with serum ferritin greater than 1000 µg/L to 
undergo liver biopsy.
In this current study, we investigated the relationship between HIC, age, serum ferritin and mobilisable iron 
in the prediction of advanced fibrosis to confirm, and extend an earlier study which demonstrated the product of 
HIC and age improved accuracy for the prediction of advanced fibrosis in patients with HH12. Our results suggest 
that the effect of duration of exposure to elevated hepatic iron stores was more important in women for the pre-
diction of advanced fibrosis (F3-F4). A sub-analysis of our data for the prediction of F2-F4 fibrosis demonstrated 
that the accuracy of HIC is similarly improved by the addition of age, albeit to a lesser degree (Supplementary 
Table S1). The more significant influence of duration of exposure in women could be related to gender-related dif-
ferences in rates of iron accumulation during adult life, that is, women have lower HIC levels prior to menopause 
with an exponential increase following menopause in women21.
Furthermore, we have demonstrated that mobilisable iron is an accurate method for retrospectively deter-
mining advanced fibrosis, independent of serum ferritin and HIC. It is also less susceptible to the effects of age 
AUROC Sensitivity Specificity Cut-off z p-value
HIC
All subjects
Male
Female
0.83 (0.73–0.89)
0.79 (0.69–0.86)
0.93 (0.81–1.00)
73%
74%
80%
73%
68%
80%
>200
>200
>197
1.956 0.050
HIC × [age]
All subjects
Male
Female
0.82 (0.76–0.90)
0.79 (0.74–0.90)
0.97 (0.67–1.00)
73%
70%
100%
74%
70%
87%
>9183
>9152
>10400
1.982 0.047
Mobilisable iron
All subjects
Male
Female
0.92 (0.88–0.96)
0.88 (0.82–0.94)
0.99 (0.98–1.00)
83%
79%
79%
83%
79%
79%
9.6
10.8
9.9
Mobilisable iron × [age]
All subjects
Male
Female
0.93 (0.88–0.97)
0.89 (0.83–0.95)
1.00 (1.00–1.00)
87%
79%
100%
88%
79%
100%
467
495
577
0.759 0.448
Serum Ferritin
All subjects
Male
Female
0.94 (0.91–0.97)
0.92 (0.87–0.96)
0.99 (0.96–1.00)
85%
82%
100%
85%
81%
98%
>1665
>1826
>1665
0.472 0.637
Table 3. ROC analysis reporting AUROC, sensitivity, specificity for HIC (µmol/g); HIC × [age] (µmol/g.yr); 
Mobilisable iron (g); Mobilisable iron × [age] (g.yr); serum ferritin (µg/L) in the detection of advanced hepatic 
fibrosis in HH subjects. 95% confidence intervals are show in brackets. The AUROC for mobilisable iron was 
compared with each of the other parameters using the method of Hanley and McNeil, generating a z-score and 
p-value17. AUROC, area under the receiver operator characteristic; HIC, hepatic iron concentration.
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(presumably because mobilisable iron in itself is a fairly accurate test). Additionally, comparison of the ROC 
curves demonstrated that mobilisable iron was at the least an equivalent test compared with mobilisable iron × 
[age] or serum ferritin levels. Mobilisable iron was superior to both HIC and HIC × [age] in predicting advanced 
hepatic fibrosis. A prior study by Phatak et al. also showed that mobilisable iron was an accurate and reliable 
surrogate for total body iron13. One potential limitation of using mobilisable iron to predict risk of underlying 
advanced fibrosis is in the setting of significant or chronic blood loss. We found that there was significant correla-
tion between HIC and mobilisable iron with an R2 of 0.45 (r = 0.67, p < 0.0001) which is consistent with previous 
studies13,22. To assess the effect of co-factors, we performed a multivariable analysis which demonstrated that the 
association of mobilisable iron and age with advanced fibrosis was independent of alcohol intake. Furthermore, 
mean alcohol intake in the study population was well below the threshold generally considered significant for 
alcohol-related liver disease as per our inclusion criteria.
Limitations of our study include the retrospective design and absence of data regarding body mass index 
(BMI) in a number of subjects. Additionally, while a majority of competing risk factors for hepatic fibro-
sis were excluded in our subjects, complete data regarding steatosis or steatohepatitis assessment on histology 
was not available as a number of cases were historical, before formalization of scoring systems were routinely 
Figure 1. Box and whisker plot demonstrating mean values for all subjects, with or without advanced fibrosis 
with proposed cut-off levels for predicting advanced fibrosis (F3-F4) in HH patients (dotted lines). For HIC (A), 
HIC × age (B), mobilisable iron (C), mobilisable iron × age (D) and serum ferritin (E).
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implemented. Additionally, although this cohort contained a relatively low number of subjects with advanced 
fibrosis, this study represents one of the largest cohorts of subjects with HH and biopsy-staged hepatic fibrosis 
providing confidence in the robustness of the data reported.
conclusion
Measurement of body iron stores by mobilisable iron (±age) can be used to predict the likelihood of significant 
hepatic fibrosis in HH and thus justify the need for more specific, but costly and invasive tests such as liver 
biopsy. Mobilisable iron stores of greater than 9.9 g in women and 10.8 g in men demonstrates high utility in the 
prediction of advanced fibrosis. This can be used to guide appropriate stratification of management for potential 
complications of chronic liver disease.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
Figure 2. Correlation between (A) HIC and mobilisable and (B) serum ferritin level and mobilisable iron. The 
95% confidence intervals are shown on the graphs as dotted lines.
Odds Ratio (95% 
confidence intervals)
p(unitalicize 
the p please)
Alcohol intake 1.02 (1.004–1.029) 0.01
Age 1.042 (1.006–1.079) 0.02
HIC 1.009 (1.006–1.013) <0.001
Mobilisable iron 1.064 (1.011–1.120) 0.02
Table 4. Multivariable logistic regression analysis of factors associated with prediction of advanced fibrosis in 
all subjects with HH. Adjusted for serum ferritin and sex.
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